XML 80 R49.htm IDEA: XBRL DOCUMENT v3.22.1
Note 4 - Collaboration Revenue (Details Textual)
$ / shares in Units, $ in Thousands, ¥ in Billions
 1 Months Ended 12 Months Ended 31 Months Ended
Nov. 12, 2020
$ / shares
shares
Nov. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Nov. 12, 2022
$ / shares
shares
Sep. 30, 2021
USD ($)
Sep. 30, 2021
CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax     $ 1,351 $ 180 $ 0      
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]                
Collaboration Agreement, Upfront Cash Payment             $ 31,039 ¥ 0.2
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]                
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value       5,267        
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]                
Collaborative Arrangement, Upfront Cash Payment   $ 10,000   9,455        
Derivative Liability, Total       278        
Proceeds from Issuance or Sale of Equity, Total       15,000        
Revenue from Contract with Customer, Including Assessed Tax     1,351 $ 180        
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received             108,638 0.7
Collaboration Agreement, Maximum Commercial Milestones to be Received             $ 62,079 ¥ 0.4
Revenue from Contract with Customer, Excluding Assessed Tax, Total     $ 0          
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]                
Stock Issued for Transfer of Assets, Shares (in shares) | shares 9,631,941              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,194,030              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,990,000              
Shares Issued, Price Per Share (in dollars per share) | $ / shares $ 2.5125              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member] | Forecast [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares           1,990,000    
Shares Issued, Price Per Share (in dollars per share) | $ / shares           $ 2.5125    
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]                
Collaborative Arrangement, Equity Investment   $ 780,000